Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Edotecarin · 3 trials · 4 indications
| Name | Type | Description |
|---|---|---|
| Edotecarin | DRUG | - |
| Temozolomide | DRUG | - |
| Carmustine (BCNU) | DRUG | - |
| Lomustine (CCNU) | DRUG | - |
Inclusion Criteria: * Must have biopsy-proven GBM. First relapse (progression or recurrence) of GBM after surgery (or biopsy) and treatment with radiotherapy (conventional fractionated external beam) and chemotherapy (temozolomide- or nitrosurea-based therapy) * Must have past biopsy samples availa...
Edotecarin was studied in oncology for the treatment of breast neoplasms, glioblastoma, and stomach neoplasms. Clinical trials evaluated it in patients with advanced gastric cancer that progressed or recurred after chemotherapy, in glioblastoma multiforme, and in women with metastatic breast cancer whose disease worsened after anthracycline and taxane therapy.
Edotecarin targets topoisomerase I (TOP1). It is a small molecule inhibitor of this enzyme. By inhibiting TOP1, edotecarin interferes with DNA replication and transcription, which is the mechanistic basis for its investigation as an anticancer agent in solid tumors.
Edotecarin is developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer sponsored the clinical trials evaluating edotecarin in gastric cancer, glioblastoma, and metastatic breast cancer.
Edotecarin is in Phase 2 development. It is an investigational small molecule and is not approved for any indication. The clinical program includes Phase 2 studies in gastric and breast cancers and a Phase 3 study in glioblastoma, all of which are completed.
Edotecarin has been evaluated in three completed trials: NCT00087503, a Phase 2 study in advanced gastric cancer; NCT00068952, a Phase 3 study in glioblastoma multiforme; and NCT00067314, a Phase 2 study in metastatic breast cancer. All three trials are completed and no active trials are ongoing.